Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | FTD/TPI and bevacizumab versus FTD/TPI monotherapy in metastatic CRC

Trifluridine/tipiracil (FTD/TPI) is currently approved for refractory metastatic colorectal cancer (mCRC). Whilst FTP/TPI plus bevacizumab has shown efficacy and tolerability in Phase I and Phase II trials, few studies have compared FTD/TPI plus bevacizumab versus FTD/TPI alone in mCRC. Takayuki Yoshino, MD, PhD, National Cancer Center Hospital, Chiba, Japan, discusses a meta-analysis conducted to compare FTD/TPI plus bevacizumab with FTD/TPI monotherapy in mCRC. Overall, the meta-analysis indicated the combination to be superior, with a similar safety profile, although associated with a higher rate of grade 3 or more neutropenia. Confirmation of these findings via trials, such as the Phase III SUNLIGHT (NCT04737187) study, are warranted. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.